Clinical Studies in Patients with Solid Tumors using a Second-Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I

S. Mani, S. Goel, M. Nesterova, R. M. Martin, J. M. Grindel, M. L. Rothenberg, R. Zhang, G. Tortora, Y. S. Cho-Chung

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical Studies in Patients with Solid Tumors using a Second-Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences

Arts & Humanities